Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.

Cristina MüllerChristoph A UmbrichtNadezda GrachevaViviane J TschanGiovanni PellegriniPeter BernhardtJan Rijn ZeevaartUlli KösterRoger SchibliNicholas P van der Meulen

Published in: European journal of nuclear medicine and molecular imaging (2019)

161Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of 161Tb-PSMA-617 for the treatment of mCRPC.

Keyphrases

pet ct
pet imaging
prostate cancer
mycobacterium tuberculosis
positron emission tomography
radical prostatectomy
molecular dynamics
stem cells
mesenchymal stem cells
molecular dynamics simulations
bone marrow
smoking cessation